Tris Pharma, Inc. v. Actavis Laboratories FL, Inc., No. 2021-1495 (July 7, 2022) (nonprecedential); Patent No(s). 8,465,765; 8,563,033; 8,778,390

Key point(s):
• A hypothetical, aspirational disclosure in prior art may not be sufficient to motivate or suggest a claimed element or combination.

Correll v. Vidal, No. 2022-1420 (July 8, 2022) (nonprecedential)

Key point(s):
• 18 U.S.C. §§ 203 and 205 apply to a federal employee representing others before the United States Patent and Trademark Office (PTO).
• The statute-of-limitations in 35 U.S.C. § 32 is not limited to only patents.